Trial Profile
Study of continuous vaccination with epitope peptides for unresectable pancreatic cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs OCV C01 (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- 18 May 2016 New trial record